Locally injectable composite hydrogel for resisting narrow outflow tract of internal arteriovenous fistula and preparation method of locally injectable composite hydrogel

Through local injection of thermosensitive hydrogel-loaded fenellone, the high cost and systemic drug adverse reactions in the treatment of arteriovenous fistula stenosis were solved, and effective inhibition of neoplasmic hyperplasia and vascular remodeling were achieved. Improved patency of arteriovenous fistula.

CN118948750APending Publication Date: 2024-11-15THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411041645.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing methods for treating arteriovenous fistula stenosis have high cost and adverse reactions from systemic drug treatment, and it is difficult to effectively improve neoplasmic hyperplasia, resulting in limited patency of arteriovenous fistula.

Method used

The temperature-sensitive hydrogel loaded with felenelone and/or polymer particles can be used to achieve long-term drug release through local injection, inhibit neointimal hyperplasia and improve vascular remodeling.

Benefits of technology

Through local injection of temperature-sensitive hydrogel-loaded fenellone, effective treatment of outflow stenosis of arteriovenous fistula is achieved, reducing the risk of systemic toxicity of the drug, improving the treatment effect and patient safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948750A_ABST
    Figure CN118948750A_ABST
Patent Text Reader

Abstract

The invention provides a locally injectable composite hydrogel for resisting narrow outflow tract of arteriovenous fistula. The locally injectable composite hydrogel comprises a temperature-sensitive hydrogel and fenerenone and / or polymer particles loaded on the temperature-sensitive hydrogel, and the polymer particles are loaded with fenerenone. Compared with the prior art, the composite hydrogel provided by the invention is formed by dispersing the fenerenone and / or the polymer particles loaded with the fenerenone in the temperature-sensitive hydrogel, and the composite hydrogel can be locally injected, loaded with drugs and released for a long time, and is simple to operate and good in in-vivo treatment effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of nano-medicine, and in particular relates to a locally injectable composite hydrogel for resisting stenosis of arteriovenous fistula outflow tract and a preparation method thereof. Background Art

[0002] Hemodialysis remains the main renal replacement therapy, and a well-functioning dialysis access with few complications is essential. Arteriovenous fistula (AVF) has sufficient blood flow, low infection rate, and repeatable puncture, making it the preferred access type in clinical practice. However, AVF failure is a difficult clinical problem that seriously affects the long-term patency of the access. Stenosis is the pathological basis of AVF failure and the primary breakthrough in improving AVF patency.

[0003] Neointimal hyperplasia is the main cause of stenosis. The current clinical treatment for arteriovenous fistula stenosis is mainly balloon dilatation. The high cost and painful treatment often make patients lose confidence in treatment. Studies including oral aspirin, clopidogrel, dipyridamole, and warfarin have not shown significant benefits in improving neointimal hyperplasia. The main limitation of systemic drug therapy is dose-limiting toxicity. Local interventions, such as mechanical devices, local drug delivery, and cell therapy, have the potential to improve AVF stenosis by providing direct therapeutic effects at the anastomosis site without the risk of systemic toxicity. Local release drug therapy can provide higher doses of drugs for arteriovenous fistulas while avoiding adverse reactions associated with systemic therapeutic drugs.

[0004] Mineralocorticoid receptors (MR) are widely expressed in kidney, heart, blood vessels and other tissues, and participate in the body's water and salt regulation, myocardial remodeling and vascular remodeling. The classic mode of action of aldosterone is through the mineralocorticoid receptors in the cytoplasm. Studies have reported that mineralocorticoid receptor antagonists (MRA) can improve vascular remodeling after vein transplantation in mice, inhibit neointimal hyperplasia and increase the patency of graft veins. They can also improve the formation of neointimal tissue after guidewire injury in the mouse carotid artery and improve vascular remodeling.

[0005] In view of the above background, the present invention intends to use hydrogel to load finerenone to prepare injectable hydrogel, and locally release drugs for a long time to improve the neointimal hyperplasia of arteriovenous fistula. Summary of the invention

[0006] In view of this, the technical problem to be solved by the present invention is to provide a locally injectable composite hydrogel for preventing arteriovenous fistula outflow tract stenosis and a preparation method thereof.

[0007] The invention provides a locally injectable composite hydrogel for preventing arteriovenous fistula outflow tract stenosis, comprising a thermosensitive hydrogel and finerenone and / or polymer particles loaded on the thermosensitive hydrogel; the polymer particles are loaded with finerenone.

[0008] Preferably, the composite hydrogel comprises a thermosensitive hydrogel and finerenone loaded on the thermosensitive hydrogel; the mass ratio of the thermosensitive gel material to the finerenone in the thermosensitive hydrogel is 1:3×10 -4 ~7×10 -4 .

[0009] Preferably, the composite hydrogel comprises a thermosensitive hydrogel and polymer particles loaded on the thermosensitive hydrogel; the mass ratio of the thermosensitive gel material in the thermosensitive hydrogel to the finerenone in the polymer particles is 1:1.3×10 -3 ~2.85×10 -3 .

[0010] Preferably, the thermosensitive hydrogel is formed of a thermosensitive gel material; the thermosensitive gel material includes one or more of hyaluronic acid, chitosan, polyacrylic acid and its derivatives, polyvinyl alcohol, polyoxyethylene, polyacrylamide and polyoxyethylene polyoxypropylene ether block copolymer.

[0011] Preferably, the finerenone and / or polymer particles are loaded on the hydrogel via chemical bonds and / or physical methods; the chemical bonds include one or more of ionic bonds, coordination bonds and hydrogen bonds.

[0012] Preferably, the polymer particles are prepared by liposome drug delivery method, nanoparticle drug delivery method, metal nanoparticle drug delivery method, nanohydrogel drug delivery method or polymer micelle drug delivery method.

[0013] Preferably, the polymer in the polymer particles is selected from one or more of polylactic acid-co-glycolic acid, polycaprolactone, polyglycolic acid, polylactic acid-co-glycolic acid, poly(3-hydroxybutyrate-co-4-hydroxybutyrate), polylactic acid, poly-L-lactide-caprolactone and polydioxanone.

[0014] The present invention also provides a method for preparing a locally injectable composite hydrogel for preventing arteriovenous fistula outflow tract stenosis, comprising the following steps:

[0015] The thermosensitive gel material is dissolved in a buffer solution under low temperature conditions, and then finerenone and / or polymer particles are added and heated to form a gel to obtain a composite hydrogel for local injectable application against arteriovenous fistula outflow tract stenosis; the polymer particles are loaded with finerenone.

[0016] Preferably, the polymer particles are prepared according to the following method:

[0017] S1) dissolving the polymer in an organic solvent, and then adding finerenone to obtain a mixed solution;

[0018] S2) ultrasonically mixing the mixed solution with an aqueous solution containing an emulsifier, and removing the organic solvent to obtain polymer particles.

[0019] The present invention also provides a use of the composite hydrogel in preparing a medicine for treating arteriovenous fistula outflow tract stenosis and / or venous graft stenosis.

[0020] The present invention provides a composite hydrogel for local injectable application for preventing arteriovenous fistula outflow tract stenosis, comprising a thermosensitive hydrogel and finerenone and / or polymer particles loaded on the thermosensitive hydrogel; the polymer particles are loaded with finerenone. Compared with the prior art, the composite hydrogel provided by the present invention is formed by dispersing finerenone and / or polymer particles loaded with finerenone in the thermosensitive hydrogel, which can be locally injected, loaded with drugs and released for a long time, is simple to operate, and has a good in vivo therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 The photos of the composite hydrogels obtained in Comparative Example 2 and Examples 6 to 10 of the present invention and the transmission electron microscope (TEM) images of PLGA nanoparticles without drug loading and drug loading;

[0022] Figure 2 This is a statistical analysis data diagram of the eNOS gene expression of endothelial cells after treatment in the embodiments of the present invention and the comparative examples;

[0023] Figure 3 HE staining images of rats treated with carotid artery-external jugular vein arteriovenous fistula 21 days after the present invention Examples 1 to 10 and Comparative Examples 1 and 2;

[0024] Figure 4 Ultrasonic detection images of rat arteriovenous fistula treated with Example 8 of the present invention and Comparative Example 2 for 21 days;

[0025] Figure 5 This is a statistical analysis data diagram of the outflow tract vein lumen diameter and blood flow of rat arteriovenous fistula treated with Example 8 of the present invention and Comparative Example 2 for 21 days;

[0026] Figure 6 HE staining images of rats treated with external jugular vein-carotid artery transplantation 21 days after Example 8 and Comparative Example 2;

[0027] Figure 7This is a statistical analysis data graph of the intramucosal thickness 21 days after external jugular vein-carotid artery transplantation in rats treated with Example 8 of the present invention and Comparative Example 2. DETAILED DESCRIPTION

[0028] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0029] The invention provides a locally injectable composite hydrogel for preventing arteriovenous fistula outflow tract stenosis, comprising a thermosensitive hydrogel and finerenone and / or polymer particles loaded on the thermosensitive hydrogel; the polymer particles are loaded with finerenone.

[0030] According to the present invention, the thermosensitive hydrogel is formed by a thermosensitive gel material; the thermosensitive gel material preferably includes one or more of hyaluronic acid, chitosan, polyacrylic acid and its derivatives, polyvinyl alcohol, polyoxyethylene, polyacrylamide and polyoxyethylene polyoxypropylene ether block copolymer; in a specific embodiment provided by the present invention, the thermosensitive gel material is a polyoxyethylene polyoxypropylene ether block copolymer (F127); the thermosensitive gel material forms a thermosensitive hydrogel through one or more of temperature-induced polymer chain entanglement, molecular self-assembly, ionic gelation, electrostatic interaction and chemical crosslinking.

[0031] According to the present invention, the polymer particles are preferably polymer nanoparticles; the particle size of the polymer particles is preferably 100-600 nm, more preferably 200-500 nm, more preferably 300-450 nm, more preferably 350-400 nm, and most preferably 370-400 nm.

[0032] According to the present invention, the polymer in the polymer particles is preferably one or more of polylactic acid-glycolic acid copolymer, polycaprolactone, polyglycolic acid, polylactic acid-glycolic acid copolymer, poly(3-hydroxybutyrate-co-4-hydroxybutyrate), polylactic acid, poly-L-lactide-caprolactone and polydioxanone; the molecular weight of the polymer is preferably 10,000 to 50,000, more preferably 20,000 to 30,000.

[0033] According to the present invention, the polymer particles are preferably prepared by liposome drug delivery method, nanoparticle drug delivery method, metal nanoparticle drug delivery method, nanohydrogel drug delivery method or polymer micelle drug delivery method.

[0034] According to the present invention, the finerenone and / or polymer particles are loaded on the thermosensitive hydrogel. Specifically, the finerenone and / or polymer particles are loaded on the hydrogel via chemical bonds and / or physical methods; the chemical bonds include one or more of ionic bonds, coordination bonds and hydrogen bonds.

[0035] In a specific embodiment provided by the present invention, the composite hydrogel comprises a thermosensitive hydrogel and finerenone loaded on the thermosensitive hydrogel; the mass ratio of the thermosensitive gel material to the finerenone in the thermosensitive hydrogel is preferably 1:3×10 -4 ~7×10 -4 In some embodiments provided by the present invention, the mass ratio of the thermosensitive gel material to finerenone in the thermosensitive hydrogel is specifically 1:3×10 -4 , 1:5×10 -4 or 1:7×10 -4 .

[0036] In another specific embodiment provided by the present invention, the composite hydrogel comprises a thermosensitive hydrogel and polymer particles loaded on the thermosensitive hydrogel; the mass ratio of the thermosensitive gel material in the thermosensitive hydrogel to the finerenone in the polymer particles is preferably 1:1.3×10 -3 ~2.85×10 -3 In some embodiments provided by the present invention, the mass ratio of the thermosensitive gel material in the thermosensitive hydrogel to the phenerenone in the polymer particles is specifically 1:1.3×10 -3 , 2.05:1.3×10 -3 or 1:2.85×10 -3 .

[0037] The composite hydrogel provided by the present invention is formed by dispersing finerenone and / or polymer particles loaded with finerenone in a thermosensitive hydrogel, which can be locally injected, loaded with drugs and released for a long time, is easy to operate, and has a good in vivo therapeutic effect.

[0038] The present invention also provides a method for preparing the above-mentioned locally injectable composite hydrogel for combating arteriovenous fistula outflow tract stenosis, comprising the following steps: dissolving a thermosensitive gel material in a buffer solution under low temperature conditions, then adding finerenone and / or polymer particles, heating to form a gel, and obtaining the locally injectable composite hydrogel for combating arteriovenous fistula outflow tract stenosis; the polymer particles are loaded with finerenone.

[0039] The present invention has no special restrictions on the sources of all raw materials, and any raw materials available on the market can be used; the temperature-sensitive gel material and polymer particles are the same as described above and will not be described in detail here.

[0040] In a specific embodiment provided by the present invention, the preparation method of the composite hydrogel comprises the following steps: dissolving the thermosensitive gel material in a buffer solution under low temperature conditions, then adding finerenone, heating to form a gel, and obtaining a composite hydrogel for local injectable application against arteriovenous fistula outflow tract stenosis; the temperature of the low temperature condition is preferably an ice bath; the buffer solution can be a buffer solution well known to those skilled in the art, and there is no special limitation, and in the present invention, it is preferably a PBS buffer solution; the pH value of the PBS buffer solution is preferably 7.0; the ratio of the thermosensitive gel material to the buffer solution is preferably 1g: (4-6)mL, more preferably 1g: (4.5-5.5)mL, and more preferably 1g: 5mL; the temperature of heating to form a gel is preferably 35°C to 37°C, more preferably 36°C to 37°C.

[0041] In another specific embodiment provided by the present invention, the preparation method of the composite hydrogel comprises the following steps: dissolving the thermosensitive gel material in a buffer solution under low temperature conditions, then adding polymer particles, heating to form a gel, and obtaining a composite hydrogel for local injectable application against arteriovenous fistula outflow tract stenosis; the temperature of the low temperature condition is preferably an ice bath; the buffer solution can be a buffer solution well known to those skilled in the art, and there is no special limitation, and PBS buffer solution is preferably used in the present invention; the pH value of the PBS buffer solution is preferably 7.0; the ratio of the thermosensitive gel material to the buffer solution is preferably 1g: (4-6)mL, more preferably 1g: (4.5-5.5)mL, and more preferably 1g: 5mL; the temperature of heating to form a gel is preferably 35°C to 37°C, more preferably 36°C to 37°C.

[0042] In another specific embodiment provided by the present invention, the polymer particles are prepared according to the following method: S1) dissolving a polymer in an organic solvent, and then adding finerenone to obtain a mixed solution; S2) ultrasonically mixing the mixed solution with an aqueous solution containing an emulsifier, and removing the organic solvent to obtain polymer particles; the polymer is preferably one or more of polylactic acid-co-glycolic acid, polycaprolactone, polyglycolic acid, polylactic acid-co-glycolic acid, poly(3-hydroxybutyrate-co-4-hydroxybutyrate), polylactic acid, poly-L-lactide-caprolactone and polydioxanone; the organic solvent is an organic solvent well known to those skilled in the art, namely The ratio of the polymer to the organic solvent is preferably 0.3 g: (2-4) mL, more preferably 0.3 g: (2-3) mL, and more preferably 0.3 g: 2.5 mL; after the polymer is completely dissolved in the organic solvent, finerenone is added, and the mass ratio of the polymer to finerenone is preferably 3000: (2-4); in some embodiments provided by the present invention, the mass ratio of the polymer to finerenone is specifically 3000: 2, 3000: 3 or 3000: 4; the mass concentration of the emulsifier in the aqueous solution containing the emulsifier is preferably 1% to 2%, more preferably 1%; the emulsifier is The emulsifiers well known to those skilled in the art can be used without any special restrictions. In the present invention, polyvinyl alcohol is preferably used. In the present invention, the aqueous solution containing the emulsifier is preferably added dropwise to the mixed solution, and after the addition is completed, ultrasonic mixing is performed. The power of the ultrasonic mixing is preferably 60 to 70 W, more preferably 65 W. The time of the ultrasonic mixing is preferably 1 to 5 min, more preferably 2 to 3 min, and more preferably 2 min. The method for removing the organic solvent is preferably volatilization, more preferably volatilization under stirring. After removing the organic solvent, the polymer particles are preferably obtained by centrifugation, washing, and drying. The speed of the centrifugation is preferably 10000 to 15000 rpm, more preferably 1 1000~14000rpm, more preferably 12000~13000rpm; the centrifugal temperature is preferably 2℃~6℃, more preferably 4℃; the centrifugal time is preferably 5~10min, more preferably 7min; the washing is preferably carried out with deionized water; the emulsifier is removed by washing; the drying is preferably freeze-drying; the freeze-drying temperature is preferably -85℃~-70℃, more preferably -80℃~-75℃, more preferably -78℃; the freeze-drying pressure is preferably 3~8Pa, more preferably 4~6Pa, more preferably 5Pa; the freeze-drying time is preferably 20~30h, more preferably 24h.

[0043] The present invention also provides an application of the composite hydrogel in preparing a medicine for treating arteriovenous fistula outflow tract stenosis and / or venous graft stenosis.

[0044] To further illustrate the present invention, a locally injectable composite hydrogel for preventing arteriovenous fistula outflow tract stenosis and a preparation method thereof provided by the present invention are described in detail below in conjunction with examples.

[0045] The reagents used in the following examples are all commercially available; the polylactic acid-glycolic acid copolymer used in the examples is derived from (PLGA50 / 50COOH, molecular weight 20,000); polyvinyl alcohol is derived from (Sigma-aldrich, molecular weight 30,000-70,000).

[0046] Example 1

[0047] 100 mg of polyoxyethylene polyoxypropylene ether block copolymer (F127) was dissolved in 500 μL PBS (pH 7.0) by stirring in an ice bath, 10 μg of finerenone (Finerenone, Fin) was added and stirred evenly, and the mixture was allowed to stand at 37 °C for 1 min to form a gel, which was named F127-Fin10. The mass ratio of finerenone to F127 was 1.0×10 -4 :1.

[0048] Example 2

[0049] The preparation method was the same as in Example 1, but 30 μg of Fin was added, named F127-Fin30, and the mass ratio of finerenone to F127 was 3.0×10 -4 :1.

[0050] Example 3

[0051] The preparation method was the same as in Example 1, but 50 μg of Fin was added, named F127-Fin50, and the mass ratio of finerenone to F127 was 5.0×10 -4 :1.

[0052] Example 4

[0053] The preparation method was the same as in Example 1, but 70 μg of Fin was added, named F127-Fin70, and the mass ratio of finerenone to F127 was 7.0×10 -4 :1.

[0054] Example 5

[0055] The preparation method was the same as in Example 1, but 100 μg of Fin was added, named F127-Fin100, and the mass ratio of finerenone to F127 was 1.0×10 -3 :1.

[0056] Example 6

[0057] Polylactic acid-co-glycolic acid (PLGA) was used as the raw material, 300 mg PLGA was dissolved in 2.5 mL dichloromethane organic solution, and 100 μg of Fin was added after PLGA was completely dissolved. The final concentration of Fin dissolved in the above mixed organic solution was 105.8 mol / L. 1% polyvinyl alcohol (PVA) was added dropwise to the above solution, and the organic solvent was volatilized overnight after 65 W power ultrasound for 2 minutes, centrifuged at 12000 rpm, 7 minutes, and 4°C, washed with deionized water 3 times to wash away PVA, freeze-dried at -78°C 5Pa for 24 hours, and then sterilized by ultraviolet for use, named Fin100 NP, the washing liquid was collected to measure the encapsulation efficiency of 50%, and the mass of loaded phenerenone was 50 μg.

[0058] 100 mg of hydrogel polyoxyethylene polyoxypropylene ether block copolymer (F127) was dissolved in 500 μL PBS in an ice bath by stirring, and 210 mg of Fin100 NP was added and stirred evenly. The mixture was gelled at 37 °C and named F127-Fin100 NP. The mass ratio of finerenone to F127 was 5 × 10 -4 :1.

[0059] Example 7

[0060] The preparation method is the same as Example 6, but 200 μg of Fin is added, and the final concentration of Fin dissolved in the mixed organic solution is 211.6 mol / L. The prepared PLGA nanoparticles loaded with Fin are named Fin200NP, with an encapsulation efficiency of 65% and a loaded finerenone mass of 130 μg.

[0061] 100 mg F127 was dissolved in 500 μL PBS by stirring in an ice bath, 210 mg Fin200 NP was added to F127 and stirred evenly, and gelled at 37 °C. The gel was named F127-Fin200 NP. The mass ratio of finerenone to F127 was 1.3 × 10 -3 :1.

[0062] Example 8

[0063] The preparation method is the same as Example 6, but 300 μg of Fin is added, and the final concentration of Fin dissolved in the mixed organic solution is 317.4 mol / L. The prepared PLGA nanoparticles loaded with Fin are named Fin300NP, with an encapsulation efficiency of 68.5% and a loading amount of finerenone of 205 μg.

[0064] 100 mg of F127 was dissolved in 500 μL PBS in an ice bath by stirring, and 210 mg of Fin300 NP was added and stirred evenly. The mixture was gelled at 37 °C and named F127-Fin300 NP. The mass ratio of finerenone to F127 was 2.05 × 10 -3 :1.

[0065] Example 9

[0066] The preparation method is the same as Example 6, but 400 μg of Fin is added, and the final concentration of Fin dissolved in the mixed organic solution is 423.2 mol / L. The prepared PLGA nanoparticles loaded with Fin are named Fin400NP, with an encapsulation efficiency of 71.25% and a loading amount of finerenone of 285 μg.

[0067] 100 mg of F127 was dissolved in 500 μL PBS in an ice bath by stirring, and 210 mg of Fin400 NP was added and stirred evenly. The mixture was gelled at 37 °C and named F127-Fin400 NP. The mass ratio of finerenone to F127 was 2.85 × 10 -3 :1.

[0068] Example 10

[0069] The preparation method is the same as that in Example 6, but 500 μg of Fin is added, and the final concentration of Fin dissolved in the mixed organic solution is 529.0 mol / L. The prepared PLGA nanoparticles loaded with Fin are named Fin500NP, with an encapsulation efficiency of 75% and a loading amount of finerenone of 375 μg.

[0070] 100 mg of F127 was dissolved in 500 μL PBS in an ice bath by stirring, and 210 mg of Fin500 NP was added and stirred evenly. The mixture was gelled at 37 °C and named F127-Fin500 NP. The mass ratio of finerenone to F127 was 3.75 × 10 -3 :1.

[0071] Comparative Example 1

[0072] 100 mg of F127 was dissolved in 500 μL PBS with stirring in an ice bath and formed into a gel at 37°C, which was named F127.

[0073] Comparative Example 2

[0074] Using PLGA as the raw material, 300 mg PLGA was dissolved in 2.5 mL dichloromethane organic solution, 1% polyvinyl alcohol (PVA) solution was added dropwise to the above solution, and the organic solvent was mixed by stirring overnight after ultrasonication. The mixture was centrifuged at 12000 rpm, 7 min, and 4 °C, washed with deionized water for 3 times to remove PVA, freeze-dried, and sterilized by UV for use, named NP. 100 mg F127 was dissolved in 500 μL PBS by stirring in an ice bath, 210 mg NP was added and stirred evenly, and gelled at 37 °C, named F127-NP.

[0075] In order to further illustrate the beneficial effects of the present invention, the following tests are performed:

[0076] 1. Structural characterization:

[0077] The parameters of Examples 1 to 10 and Comparative Examples 1 and 2 were analyzed, and the results are shown in Table 1. There is no difference in the particle size of the PLGA nanoparticles of Examples 6 to 10 and Comparative Example 2. Figure 1 The following are photos of the composite hydrogels obtained in Comparative Example 2 and Examples 6 to 10 and transmission electron microscopy images of the drug-loaded nanoparticles. Transmission electron microscopy (TEM) images show that the drug-loaded nanoparticles in Comparative Example 2 and Examples 6 to 10 have similar structures ( Figure 1 ), the PLGA nanoparticles are spherical with relatively uniform size. Compared with Comparative Example 2, the potentials of Examples 6 to 10 are slightly increased, all of which are negative values ​​(Table 1); these results indicate that the PLGA nanoparticles loaded with Fin are uniformly distributed negatively charged nanoparticles.

[0078] Table 1 Parameters of Examples and Comparative Examples

[0079]

[0080]

[0081] 2. Fin release detection

[0082] The release rates of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 were respectively tested in 15 mL of PBS solution (pH 7.0) at 37° C., and 50 μL was taken at specific time points for detection using liquid chromatography mass spectrometry (LCMS). Examples 1 to 5 were rapidly released in the first 4 days, with a release amount of more than 90%. Examples 6 to 10 can achieve sustained release of finerenone for more than 21 days, and the sustained release rate increases with the increase in the mass ratio of finerenone to F127, as shown in Table 2.

[0083] Table 2 Example drug in vitro release rate characterization (release rate %)

[0084]

[0085]

[0086] 3. Inhibitory effect of hydrogel on smooth muscle cell proliferation

[0087] In order to evaluate the effect of hydrogel on smooth muscle cell proliferation, human umbilical artery smooth muscle cells (HUASMCs, Shanghai Aoyin Biotechnology Co., Ltd.) were seeded in 48-well plates and cultured for 7 days. The culture medium (gibco, DMEM / F-12) was replaced on days 1, 4, and 7, respectively, and the absorbance was measured using CCK-8 reagent to evaluate cell proliferation. The experiment was divided into an untreated group, a stimulation group (aldosterone was added to the culture medium at a final concentration of 500 nM), a comparative example 1 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of comparative example 1), a comparative example 2 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of comparative example 2), an example 1 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 1), an example 2 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 2), an example 3 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 3), and an example 4 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 3). M aldosterone and 10 μL of Example 4), Example 5 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 5), Example 6 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 6), Example 7 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 7), Example 8 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 8), Example 9 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 9), Example 10 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 10). The final concentration of aldosterone in the stimulation group was 500 nM to simulate the activation of smooth muscle cells after the establishment of arteriovenous fistula and the binding of aldosterone to the mineralocorticoid receptor. The significant increase in proliferation compared with the untreated group proved that the activation was successful.

[0088] The results on the first day showed that the cell proliferation in the stimulation group was significantly increased compared with that in the untreated group, indicating that the smooth muscle cells were in an activated state. There was no difference in cell proliferation between the treatment group and the stimulation group in Comparative Example 1, indicating that Comparative Example 1 had no effect on the proliferation of smooth muscle cells. The cell proliferation in the treatment groups of Examples 2, 3, 4, and 5 was significantly lower than that in the stimulation group (P < 0.05), indicating that these examples can inhibit the proliferation of smooth muscle cells. There was no difference in cell proliferation between the treatment group and the stimulation group in Example 1 because the drug concentration released by this example did not reach the drug concentration that inhibits the proliferation of smooth muscle cells; there was no difference in cell proliferation between the treatment group and the stimulation group in Comparative Example 2, indicating that Comparative Example 2 had no effect on the proliferation of smooth muscle cells. The cell proliferation in the treatment groups 7, 8, 9, and 10 in Examples was significantly lower than that in the stimulation group (P < 0.05), indicating that these examples can inhibit the proliferation of smooth muscle cells. There was no difference in cell proliferation between the treatment group and the stimulation group in Example 6 because the drug concentration released by this example did not reach the drug concentration that inhibits the proliferation of smooth muscle cells. The results on the 4th and 7th days showed that with the release of the drug, compared with the stimulation group, the treatments of Examples 1, 2, 3, 4, and 5 could significantly inhibit the proliferation of smooth muscle cells; and Examples 6, 7, 8, 9, and 10 could also significantly inhibit the proliferation of smooth muscle cells (Table 3).

[0089] Table 3 Effects of Examples and Comparative Examples on Proliferation of Human Umbilical Artery Smooth Muscle Cells (HUASMCs)

[0090]

[0091]

[0092] 4. Inhibitory effect of hydrogel on smooth muscle cell migration

[0093] In order to evaluate the effect of hydrogel on the migration of smooth muscle cells, human umbilical artery smooth muscle cells (HUASMCs) were seeded in 6-well plates and then scratched with a 1 mL blue pipette tip after they were fully grown. The 0 h was marked as photo-taking and grouping. The experiment was divided into the untreated group, the stimulated group (culture medium (gibco, DMEM / F-12 1:1), the comparative example 1 treatment group (1500 μL of medium added with aldosterone at a final concentration of 500 nM and 50 μL of comparative example 1), the comparative example 2 treatment group (1500 μL of medium added with aldosterone at a final concentration of 500 nM and 50 μL of comparative example 2), the example 1 treatment group (1500 μL of medium added with aldosterone at a final concentration of 500 nM and 50 μL of example 1), the example 2 treatment group (1500 μL of medium added with aldosterone at a final concentration of 500 nM and 50 μL of example 2), the example 3 treatment group (1500 μL of medium added with aldosterone at a final concentration of 500 nM and 50 μL of example 3), the example 4 treatment group (1500 μL of medium added with aldosterone at a final concentration of 500 nM and 50 μL of example 4), the example The Example 5 treatment group (1500 μL culture medium with a final concentration of 500 nM aldosterone and 50 μL Example 5 added), the Example 6 treatment group (1500 μL culture medium with a final concentration of 500 nM aldosterone and 50 μL Example 6 added), the Example 7 treatment group (1500 μL culture medium with a final concentration of 500 nM aldosterone and 50 μL Example 7 added), the Example 8 treatment group (1500 μL culture medium with a final concentration of 500 nM aldosterone and 50 μL Example 8 added), the Example 9 treatment group (1500 μL culture medium with a final concentration of 500 nM aldosterone and 50 μL Example 9 added), and the Example 10 treatment group (1500 μL culture medium with a final concentration of 500 nM aldosterone and 50 μL Example 10 added) were photographed at 24 h, and the percentage of smooth muscle cell migration area was calculated. The final concentration of aldosterone in the stimulation group was 500 nM to simulate the smooth muscle cells being in an activated state after the establishment of arteriovenous fistula and the binding of aldosterone to the mineralocorticoid receptor. The significant increase in migration compared to the untreated area proved that the activation was successful.

[0094] The results show that the migration of the stimulation group is significantly increased compared with the untreated group, indicating that the smooth muscle cells are in an activated state. There is no difference in the percentage of migration area between the treatment group of Comparative Example 1 and the stimulation group, indicating that Comparative Example 1 has no effect on the migration of smooth muscle cells. There is no difference in the percentage of migration area between the treatment group of Example 1 and the stimulation group, because the drug concentration released by this embodiment does not reach the drug concentration that inhibits the migration of smooth muscle cells. The cell migration of the treatment groups of Examples 2, 3, 4, and 5 is significantly reduced compared with the stimulation group, indicating that these embodiments can inhibit the migration of smooth muscle cells; there is no difference in the percentage of migration area between the treatment group of Comparative Example 2 and the stimulation group, indicating that Comparative Example 2 has no effect on the migration of smooth muscle cells. There is no difference in the percentage of migration area between the treatment group of Example 6 and the stimulation group, because the drug concentration released by this embodiment does not reach the drug concentration that inhibits the migration of smooth muscle cells. The percentage of cell migration area in the treatment groups of Examples 7, 8, 9, and 10 is significantly reduced compared with the stimulation group, indicating that these embodiments can inhibit the migration of smooth muscle cells (Table 4).

[0095] Table 4 Effect of Examples and Comparative Examples on Migration of Human Umbilical Artery Smooth Muscle Cells (HUASMCs) (Migration Area %)

[0096] 24 hours No treatment group 32.6±2.5 Stimulation Group 56.9±2.2 Comparative Example 1 Treatment Group 56.8±1.6 Comparative Example 2 Treatment Group 56.3±2.1 Example 1 Treatment Group 55.7±2.3 Example 2 Treatment Group 42.2±2.5 Example 3 Treatment Group 30.7±1.7 Example 4 Treatment Group 26.3±1.9 Example 5 Treatment Group 20.9±1.5 Example 6 Treatment Group 55.5±2.5 Example 7 Treatment Group 42.1±1.6 Example 8 Treatment Group 30.9±1.8 Example 9 Treatment Group 26.1±1.7 Example 10 Treatment Group 20.7±1.9

[0097] 5. Smooth muscle cell live or dead staining analysis

[0098] In order to evaluate the cytotoxic effect of hydrogel on smooth muscle cells, human umbilical artery smooth muscle cells (HUASMCs) were seeded in 48-well plates and cultured for 7 days. The culture medium (gibco, DMEM / F-12 1:1) was replaced on days 1, 4, and 7, respectively. The cells were stained with a live / dead staining reagent (Biyuntian Calcein / PI Cell Viability Cytotoxicity Detection Kit C2015S) on days 1, 4, and 7, and the cell survival rate was calculated to evaluate the survival. The experiment was divided into an untreated group, a stimulation group (aldosterone was added to the culture medium at a final concentration of 500 nM), a comparative example 1 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of comparative example 1), a comparative example 2 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of comparative example 2), an example 1 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 1), an example 2 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 2), an example 3 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 3), and an example 4 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 3). M aldosterone and 10 μL of Example 4), Example 5 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 5), Example 6 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 6), Example 7 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 7), Example 8 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 8), Example 9 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 9), Example 10 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 10). The final concentration of aldosterone in the stimulation group was 500 nM to simulate the activation state of smooth muscle cells after the binding of aldosterone and mineralocorticoid receptors after the establishment of arteriovenous fistula.

[0099] On the first day, the cell survival rate of all groups was >99%, and there was no difference in the survival rate of smooth muscle cells in the untreated group, the comparative example 1, 2 treatment groups, and the examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 treatment groups. The results on the 4th and 7th days showed that there was almost no cell death in the control group, the stimulation group, the comparative example 1, and the examples 1, 2, 3, 4 treatment groups, and the survival rate of smooth muscle cells in the example 5 treatment group was significantly lower than that in the stimulation group, the comparative example 1, and the examples 1, 2, 3, 4 groups, indicating that with the release of the drug, the drug concentration of this example was too high, and there was a toxic effect on the smooth muscle cells; there was almost no cell death in the comparative example 2 and the examples 6, 7, 8, 9 treatment groups, and the survival rate of smooth muscle cells in the example 10 treatment group was significantly lower than that in the comparative example 2 and the examples 6, 7, 8, 9 treatment groups, indicating that with the release of the drug, the drug concentration of this example was too high, and there was a toxic effect on the smooth muscle cells (Table 5). Smooth muscle cells, as the main cellular component of the vascular tunica, play a role in maintaining vascular tension. When a large number of smooth muscle cells die, the normal function of the blood vessels may be damaged. In addition, the death of smooth muscle cells will cause local inflammation, thereby causing damage to endothelial cells, affecting the integrity of the vascular endothelium, and possibly leading to the formation of blood clots.

[0100] Table 5 Toxic effects of Examples and Comparative Examples on human umbilical artery smooth muscle cells (HUASMCs) (survival rate %)

[0101]

[0102]

[0103] 6. Endothelial cell live / dead staining analysis

[0104] In order to evaluate the toxic effect of hydrogel on endothelial cells, human umbilical vein endothelial cells (HUVECs, Shanghai Aoyin Company) were seeded in 48-well plates and cultured for 7 days after adhesion. The culture medium (ECM, Sclencell, CatNo.1001) was replaced on days 1, 4, and 7, respectively. The cells were stained with a live / dead staining reagent (Biyuntian Calcein / PI Cell Activity Cytotoxicity Detection Kit C2015S) on days 1, 4, and 7, and the cell survival rate was calculated to evaluate the survival. The experiment was divided into an untreated group, a stimulation group (aldosterone was added to the culture medium at a final concentration of 500 nM), a comparative example 1 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of comparative example 1), a comparative example 2 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of comparative example 2), an example 1 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 1), an example 2 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 2), an example 3 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 3), and an example 4 treatment group (300 μL of culture medium was added with aldosterone at a final concentration of 500 nM and 10 μL of example 3). M aldosterone and 10 μL of Example 4), Example 5 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 5), Example 6 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 6), Example 7 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 7), Example 8 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 8), Example 9 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 9), Example 10 treatment group (300 μL of culture medium added with aldosterone at a final concentration of 500 nM and 10 μL of Example 10). The final concentration of aldosterone in the stimulation group was 500 nM to simulate the state of endothelial cells after aldosterone binds to the mineralocorticoid receptor after the establishment of arteriovenous fistula.

[0105] On the first day, the cell survival rate of all groups was >99%, and there was no difference in the survival rate of endothelial cells in the untreated group, the comparative example 1, 2 treatment groups, and the examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 treatment groups. The results on the 4th and 7th days showed that there was almost no cell death in the control group, the stimulation group, the comparative example 1, and the examples 1, 2, 3, 4 groups, and the cell survival rate of the example 5 treatment group was significantly reduced, indicating that with the release of the drug, the drug concentration of this example was too high, and there was a toxic effect on the endothelial cells; there was almost no cell death in the comparative example 2 and the examples 6, 7, 8, 9 groups, and the cell survival rate of the example 10 treatment group was significantly reduced, indicating that with the release of the drug, the drug concentration of this example was too high, and there was a toxic effect on the endothelial cells (Table 6). Endothelial cells are the constituent cells of the vascular endothelium. After a large number of deaths, the integrity of the vascular endothelium is affected, which may lead to the formation of thrombi, promote the further proliferation and migration of smooth muscle cells, and cause the occurrence of vascular stenosis.

[0106] Table 6 Toxicity of Examples and Comparative Examples to Human Umbilical Vein Endothelial Cells (HUVEC) (survival rate %)

[0107]

[0108]

[0109] 7. Evaluation of endothelial cell function

[0110] Since the function of endothelial cells plays a key role in the establishment of vascular remodeling of arteriovenous fistula, the present invention evaluates the function of endothelial cells at the genetic level. Human umbilical vein endothelial cells (HUVECs, Shanghai Aoyin Company) were inoculated into 6-well plates and cultured. The experiment was divided into untreated group, stimulation group (culture medium (ECM, Sclencell, Cat No.1001) with a final concentration of 500 nM aldosterone added), Comparative Example 1 treatment group (1500 μL of culture medium with a final concentration of 500 nM aldosterone and 50 μL of Comparative Example 1), Comparative Example 2 treatment group (1500 μL of culture medium with a final concentration of 500 nM aldosterone and 50 μL of Comparative Example 2), Example 1 treatment group (1500 μL of culture medium with a final concentration of 500 nM aldosterone and 50 μL of Example 1), Example 2 treatment group (1500 μL of culture medium with a final concentration of 500 nM aldosterone and 50 μL of Example 2), Example 3 treatment group (1500 μL of culture medium with a final concentration of 500 nM aldosterone and 50 μL of Example 3), Example 4 treatment group (1500 μL of culture medium with a final concentration of 500 nM aldosterone ketone and 50 μL of Example 4), Example 5 treatment group (1500 μL of culture medium added with aldosterone at a final concentration of 500 nM and 50 μL of Example 5), Example 6 treatment group (1500 μL of culture medium added with aldosterone at a final concentration of 500 nM and 50 μL of Example 6), Example 7 treatment group (1500 μL of culture medium added with aldosterone at a final concentration of 500 nM and 50 μL of Example 7), Example 8 treatment group (1500 μL of culture medium added with aldosterone at a final concentration of 500 nM and 50 μL of Example 8), Example 9 treatment group (1500 μL of culture medium added with aldosterone at a final concentration of 500 nM and 50 μL of Example 9), Example 10 treatment group (1500 μL of culture medium added with aldosterone at a final concentration of 500 nM and 50 μL of Example 10). The cells were treated for 24 hours and RNA was extracted for qPCR to measure the expression of eNOS. The experimental results are shown in the figure. Figure 2 The final concentration of aldosterone in the stimulation group was 500 nM to simulate the state of endothelial cells after aldosterone binds to the mineralocorticoid receptor after the establishment of arteriovenous fistula. The expression of eNOS in the stimulation group was significantly reduced compared with that in the untreated group, indicating that the endothelial cell function was impaired.

[0111] The results showed that compared with the untreated group, the eNOS expression level in the stimulated group was significantly reduced. There was no significant change in eNOS expression in the treatment group of Comparative Example 1 compared with the stimulation group, indicating that the treatment of Comparative Example 1 had no effect on the function of endothelial cells. After the treatment of Examples 1 and 5, there was no significant change in the eNOS expression level compared with the stimulation group. After the treatment of Examples 2, 3, and 4, the eNOS expression level was significantly increased compared with the stimulation group, and Example 3 was the most significant. After the treatment of Example 3, the eNOS expression level in the endothelial cells reached the highest value; there was no significant change in eNOS expression in the treatment group of Comparative Example 2 compared with the stimulation group, indicating that the treatment of Comparative Example 2 had no effect on the function of endothelial cells. After the treatment of Examples 6 and 10, there was no significant change in the eNOS expression level compared with the stimulation group.

[0112] After treatment in Example 7, 8, and 9, the expression of eNOS in the endothelial cells increased significantly compared to that in the stimulation group. After treatment in Example 8, the expression of eNOS in the endothelial cells reached the highest value.

[0113] Previous studies have shown that the proliferation of smooth muscle cells in the outflow vein was 40%, 120%, and 200% 1 day, 4 days, and 7 days after the establishment of the arteriovenous fistula. The results of cell proliferation and migration on the first day showed that the treatment groups of Examples 1 and 6 failed to significantly inhibit the proliferation and migration of smooth muscle compared with the stimulation group, which was due to the low concentration of drug release in this example. The results of toxic effects on smooth muscle cells and endothelial cells showed that a large number of cells in the treatment groups of Examples 5 and 10 died on the 4th and 7th days, indicating that the drug concentration of this example was too high. Further evaluation of the effect of the hydrogel on endothelial cell function found that Examples 2, 3, and 4 significantly improved the expression of endothelial cell eNOS gene, with Example 3 being the most obvious; Examples 7, 8, and 9 significantly improved the expression of endothelial cell eNOS gene, with Example 8 being the most obvious. Combined with the above in vitro study results, it is concluded that the concentration of finerenone loaded in Examples 2, 3, and 4 is a relatively ideal concentration of finerenone loaded in the hydrogel, and Example 3 has the best effect; the concentration of finerenone loaded in Examples 7, 8, and 9 is a relatively ideal concentration of finerenone loaded in the nanoparticles and then dissolved in the hydrogel, and Example 8 has the best effect.

[0114] 8. Application in rats

[0115] 1) The animal model was a Cuff fistula model of the carotid artery-external jugular vein in SD male rats (300-350 g), and the rats were randomly divided into a control group (carotid artery-external jugular vein AVF surgery was performed on rats using Cuff cannulation), a comparative example 1 treatment group (500 μL of comparative example 1 was injected on the surface of the outflow tract vein after AVF surgery), a comparative example 2 treatment group (500 μL of comparative example 2 was injected on the surface of the outflow tract vein after AVF surgery), an example 1 treatment group (500 μL of example 1 was injected on the surface of the outflow tract vein after AVF surgery), an example 2 treatment group (500 μL of example 2 was injected on the surface of the outflow tract vein after AVF surgery), an example 3 treatment group (500 μL of example 3 was injected on the surface of the outflow tract vein after AVF surgery), and an example 4 treatment group ( 500 μL of Example 4 was injected on the surface of the outflow vein after AVF surgery), Example 5 treatment group (500 μL of Example 5 was injected on the surface of the outflow vein after AVF surgery), Example 6 treatment group (500 μL of Example 6 was injected on the surface of the outflow vein after AVF surgery), Example 7 treatment group (500 μL of Example 7 was injected on the surface of the outflow vein after AVF surgery), Example 8 treatment group (500 μL of Example 8 was injected on the surface of the outflow vein after AVF surgery), Example 9 treatment group (500 μL of Example 9 was injected on the surface of the outflow vein after AVF surgery), Example 10 treatment group (500 μL of Example 10 was injected on the surface of the outflow vein after AVF surgery), 10 mice in each group, 21 days after surgery, small animal Doppler ultrasound (Vevo 2100 System, Visualsonics, Canada) was used to detect the patency, flow rate and vascular diameter of the outflow vein. After ultrasound perfusion, samples were taken for histological staining to analyze the stenosis of the vein.

[0116] Calculation of patency rate: patency rate = number of patency cases / total number of cases × 100%

[0117] Blood flow calculation: Blood flow = πr 2 ×VTI (velocity time integral), unit: mL / min. The radius and VTI were measured at the artery 5 mm away from the arterial end of the Cuff. Each animal was measured 3 times and the average value was taken. Only the unobstructed animals were measured.

[0118] Blood vessel diameter: The measurement position was 2 mm from the Cuff vein end. Each animal was measured 3 times and the average value was taken. Only the unobstructed animals were measured.

[0119] Analysis of outflow vein stenosis: Outflow tract sections 2 mm away from the Cuff vein end were taken for HE staining and then measured using ImageJ to measure the neointimal hyperplasia area and lumen area, and the ratio of the two was calculated. Only the animals with unobstructed veins were counted.

[0120] Explanation of the results for venous stenosis:

[0121] Representative HE staining of the control group, comparative examples 1, 2 and treatment groups of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 are shown in Figure 3 As shown, combined with Table 7, there is no difference in the neointima / lumen area ratio between the treatment group of Comparative Example 1 and the control group, there is no difference in the neointima / lumen area ratio between the treatment group of Example 1 and the control group, the neointima / lumen area ratio of the treatment groups of Examples 2, 3, and 4 is significantly smaller than that of the control group, the ratio of the treatment group of Example 3 is the smallest, and the neointima / lumen area ratio of the treatment group of Example 5 is greater than that of the control group; there is no difference in the neointima / lumen area ratio between the treatment group of Comparative Example 2 and the control group, there is no difference in the neointima / lumen area ratio between the treatment group of Example 6 and the control group, the neointima / lumen area ratio of the treatment groups of Examples 7, 8, and 9 is significantly smaller than that of the control group, the ratio of the treatment group of Example 8 is the smallest, and the neointima / lumen area ratio of the treatment group of Example 10 is greater than that of the control group.

[0122] Explanation of outflow vein lumen diameter and blood flow results:

[0123] According to Table 7, among all the examples, the patency rates of the treatment groups of Examples 3 and 8 were the highest, both 100%.

[0124] There was no difference in lumen diameter between the treatment group of comparative example 1 and the control group, there was no difference in lumen diameter between the treatment group of example 1 and the control group, the lumen diameters of the treatment groups of examples 2, 3, and 4 were significantly larger than those of the control group, the lumen diameter of the treatment group of example 3 was the largest, and the lumen diameter of the treatment group of example 5 was smaller than that of the control group; there was no difference in lumen diameter between the treatment group of comparative example 2 and the control group, there was no difference in lumen diameter between the treatment group of example 6 and the control group, the lumen diameters of the treatment groups of examples 7, 8, and 9 were significantly larger than those of the control group, the lumen diameter of the treatment group of example 8 was the largest, and the lumen diameter of example 10 was smaller than that of the control group. The control group, the treatment group of comparative example 2, and the treatment group of example 8 were applied to external jugular vein-carotid arteriovenous fistula ultrasound in rats as an example, as shown in the attached figure. Figure 4 As shown, 21 days after AVF was established, small animal ultrasound showed that the lumen diameter of the treatment group of Example 8 was significantly larger than that of the treatment group of Comparative Example 2 and the control group; Figure 5 Statistics of the data showed that there was no difference in the diameter of the outflow tract lumen between the control group and the comparative example 2 treatment group.

[0125] There was no difference in blood flow between the treatment group of Comparative Example 1 and the control group, there was no difference in blood flow between the treatment group of Example 1 and the control group, the blood flow of the treatment groups of Examples 2, 3, and 4 was significantly higher than that of the control group, the blood flow of the treatment group of Example 3 was the highest, and the blood flow of the treatment group of Example 5 was lower than that of the control group; there was no difference in blood flow between the treatment group of Comparative Example 2 and the control group, the blood flow of the treatment group of Example 6 was lower than that of the control group, the blood flow of the treatment groups of Examples 7, 8, and 9 was significantly higher than that of the control group, the blood flow of the treatment group of Example 8 was the highest, and the blood flow of the treatment group of Example 10 was lower than that of the control group. Taking the results of ultrasonic measurement of external jugular vein-carotid arteriovenous fistula in rats as an example, there was no difference in blood flow between the control group and the treatment group of Comparative Example 2, and the blood flow of the treatment group of Example 8 was significantly greater than that of the control group and the treatment group of Comparative Example 2 ( Figure 5 ).

[0126] The animal test data of Examples 1 to 10 and Comparative Examples 1 to 2 are shown in Table 7 below.

[0127] Table 7 Rat arteriovenous fistula detection data

[0128]

[0129]

[0130] 2) Rat external jugular vein transplantation-carotid artery transplantation model

[0131] The animal model was a Cuff model of external jugular vein-carotid artery transplantation in SD male rats (300-350 g), which were randomly divided into a control group (external jugular vein-carotid artery transplantation in rats was performed using Cuff cannulation), a comparative example 1 treatment group (500 μL of comparative example 1 was injected into the venous surface after external jugular vein-carotid artery transplantation in rats), a comparative example 2 treatment group (500 μL of comparative example 2 was injected into the venous surface after external jugular vein-carotid artery transplantation in rats), an example 1 treatment group (500 μL of example 1 was injected into the venous surface after external jugular vein-carotid artery transplantation in rats), an example 2 treatment group (500 μL of example 2 was injected into the venous surface after external jugular vein-carotid artery transplantation in rats), an example 3 treatment group (500 μL of example 3 was injected into the venous surface after external jugular vein-carotid artery transplantation in rats), and an example 4 treatment group (500 μL of example 3 was injected into the venous surface after external jugular vein-carotid artery transplantation in rats). After transplantation, 500 μL of Example 4 was injected into the vein surface), Example 5 treatment group (500 μL of Example 5 was injected into the vein surface after rat external jugular vein-carotid artery transplantation), Example 6 treatment group (500 μL of Example 6 was injected into the vein surface after rat external jugular vein-carotid artery transplantation), Example 7 treatment group (500 μL of Example 7 was injected into the vein surface after rat external jugular vein-carotid artery transplantation), Example 8 treatment group (500 μL of Example 8 was injected into the vein surface after rat external jugular vein-carotid artery transplantation), Example 9 treatment group (500 μL of Example 9 was injected into the vein surface after rat external jugular vein-carotid artery transplantation), Example 10 treatment group (500 μL of Example 10 was injected into the vein surface after rat external jugular vein-carotid artery transplantation), 10 rats in each group, 21 days after surgery, small animal Doppler ultrasound (Vevo 2100 System, Visualsonics, Canada) was used to detect the patency, flow rate and vascular diameter of the vein. After ultrasound perfusion, samples were taken for histological staining to analyze the stenosis of the vein.

[0132] Calculation of patency rate: patency rate = number of patency cases / total number of cases × 100%

[0133] Blood vessel diameter: The measurement position was the vein 2 mm away from the distal Cuff interface. Each animal was measured 3 times and the average value was taken. Only the unobstructed animals were measured.

[0134] Intimal thickness: After HE staining, the graft vein 2 mm away from the distal Cuff interface was divided into 12 parts according to the circumference of the basement membrane. The intimal thickness of the 12 parts was measured and the average value was taken. Only the animals with unobstructed veins were counted.

[0135] Analysis of graft vein stenosis: The graft vein 2 mm away from the distal Cuff interface was obtained for HE staining and measured using Image J to measure the neointimal hyperplasia area and lumen area, and the ratio of the two was calculated. Only the animals with patency were included in the analysis.

[0136] Explanation of Intima Thickness Results:

[0137] Combined with Table 8, there is no difference in intima thickness between the treatment group of Comparative Example 1 and the control group, there is no difference in intima thickness between the treatment group of Example 1 and the control group, the intima thickness of the treatment groups of Examples 2, 3, and 4 is significantly less than that of the control group, the intima thickness of the treatment group of Example 3 is the lowest, and the intima thickness of the treatment group of Example 5 is greater than that of the control group; there is no difference in intima thickness between the treatment group of Comparative Example 2 and the control group, there is no difference in intima thickness between the treatment group of Example 6 and the control group, the intima thickness of the treatment groups of Examples 7, 8, and 9 is significantly less than that of the control group, the intima thickness of the treatment group of Example 8 is the highest, and the intima thickness of the treatment group of Example 10 is greater than that of the control group. Take the control group, the treatment group of Comparative Example 2 and the treatment group of Example 8 as an example for rat external jugular vein-carotid artery transplantation, as shown in the attached figure. Figure 6 As shown, 21 days after external jugular vein transplantation, HE staining showed that the graft vein hyperplasia intima (the part above the black dotted line) in the treatment group of Example 8 was smaller than that in the treatment group of Comparative Example 2 and the control group; Figure 7 Statistics of the data showed that there was no difference in the endometrial thickness between the control group and the comparative example 2 treatment group, and the endometrial thickness of the embodiment 2 treatment group was significantly less than that of the control group and the comparative example 2 treatment group.

[0138] Description of lumen diameter and neointimal / lumen area ratio

[0139] Combined with Table 8, among all the examples, the patency rates of the groups applying Examples 3 and 8 were the highest, both 100%.

[0140] There was no difference in lumen diameter between the treatment group and the control group in Comparative Example 1, there was no difference in lumen diameter between the treatment group and the control group in Example 1, the lumen diameter of the treatment group in Examples 2, 3, and 4 was significantly larger than that of the control group, the lumen diameter of the treatment group in Example 3 was the largest, and the lumen diameter of the treatment group in Example 5 was significantly smaller than that of the control group; there was no difference in lumen diameter between the treatment group and the control group in Comparative Example 2, there was no difference in lumen diameter between the treatment group and the control group in Example 6, the lumen diameter of the treatment group in Examples 7, 8, and 9 was significantly larger than that of the control group, the lumen diameter of the treatment group in Example 8 was the largest, and the lumen diameter of the treatment group in Example 10 was significantly smaller than that of the control group.

[0141] There was no difference in the neointima / lumen area ratio between the treatment group and the control group in Comparative Example 1, there was no difference in the neointima / lumen area ratio between the treatment group and the control group in Example 1, the neointima / lumen area ratio between the treatment group and the control group in Example 2, 3, and 4 was significantly lower than that in the control group, the ratio of the treatment group in Example 3 was the smallest, and the neointima / lumen area ratio between the treatment group and the control group in Example 5 was greater than that in the control group; there was no difference in the neointima / lumen area ratio between the treatment group and the control group in Comparative Example 2, there was no difference in the neointima / lumen area ratio between the treatment group and the control group in Example 6, the neointima / lumen area ratio between the treatment group and the control group, the neointima / lumen area ratio between the treatment groups in Examples 7, 8, and 9 was significantly lower than that in the control group, the ratio of the treatment group in Example 8 was the smallest, and the neointima / lumen area ratio of the treatment group in Example 10 was greater than that in the control group.

[0142] The animal test data of Examples 1 to 10 and Comparative Examples 1 to 2 are shown in Table 8 below.

[0143] Table 8 Rat external jugular vein-carotid artery transplantation test data

[0144]

[0145] Based on the in vivo results, the treatment groups 1 and 6 failed to improve the neointimal hyperplasia of the arteriovenous fistula outflow tract and the vein graft due to low drug concentrations. The drug concentrations in Examples 5 and 10 were too high, and drug toxicity caused the death of vascular endothelial cells and smooth muscle cells, and the function of the vascular intima and media was damaged, and the stenosis of the arteriovenous fistula outflow tract and the vein graft could not be effectively inhibited. Examples 2, 3, and 4 had the effect of improving the stenosis of the arteriovenous fistula outflow tract and the vein graft, and Example 3 had the best therapeutic effect; Examples 7, 8, and 9 had the effect of improving the stenosis of the arteriovenous fistula outflow tract and the vein graft, and Example 8 had the best therapeutic effect.

[0146] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A locally injectable composite hydrogel for preventing arteriovenous fistula outflow tract stenosis, characterized in that: The invention comprises a thermosensitive hydrogel and finerenone and / or polymer particles loaded on the thermosensitive hydrogel; the polymer particles are loaded with finerenone.

2. The composite hydrogel according to claim 1, characterized in that The composite hydrogel comprises a thermosensitive hydrogel and finerenone loaded on the thermosensitive hydrogel; the mass ratio of the thermosensitive gel material to the finerenone in the thermosensitive hydrogel is 1:3×10 -4 ~7×10 -4 .

3. The composite hydrogel according to claim 1, characterized in that The composite hydrogel comprises a thermosensitive hydrogel and polymer particles loaded on the thermosensitive hydrogel; the mass ratio of the thermosensitive gel material in the thermosensitive hydrogel to the finerenone in the polymer particles is 1:1.3×10 -3 ~2.85×10 -3 .

4. The composite hydrogel according to claim 1, characterized in that The thermosensitive hydrogel is formed by a thermosensitive gel material; the thermosensitive gel material includes one or more of hyaluronic acid, chitosan, polyacrylic acid and its derivatives, polyvinyl alcohol, polyoxyethylene, polyacrylamide and polyoxyethylene polyoxypropylene ether block copolymer.

5. The composite hydrogel according to claim 1, characterized in that The finerenone and / or polymer particles are loaded on the hydrogel via chemical bonds and / or physical methods; the chemical bonds include one or more of ionic bonds, coordination bonds and hydrogen bonds.

6. The composite hydrogel according to claim 1, characterized in that The polymer particles are prepared by liposome drug loading method, nanoparticle drug loading method, metal nanoparticle drug loading method, nanohydrogel drug loading method or polymer micelle drug loading method.

7. The composite hydrogel according to claim 1, characterized in that The polymer in the polymer particles is selected from one or more of polylactic acid-co-glycolic acid, polycaprolactone, polyglycolic acid, polylactic acid-co-glycolic acid, poly(3-hydroxybutyrate-co-4-hydroxybutyrate), polylactic acid, poly-L-lactide-caprolactone and polydioxanone.

8. A method for preparing a locally injectable composite hydrogel for preventing arteriovenous fistula outflow tract stenosis, characterized in that: The following steps are involved: The thermosensitive gel material is dissolved in a buffer solution under low temperature conditions, and then finerenone and / or polymer particles are added and heated to form a gel to obtain a composite hydrogel for local injectable application against arteriovenous fistula outflow tract stenosis; the polymer particles are loaded with finerenone.

9. The preparation method according to claim 8, characterized in that: The polymer particles are prepared according to the following method: S1) dissolving the polymer in an organic solvent, and then adding finerenone to obtain a mixed solution; S2) ultrasonically mixing the mixed solution with an aqueous solution containing an emulsifier, and removing the organic solvent to obtain polymer particles.

10. Use of the composite hydrogel according to any one of claims 1 to 7 or the composite hydrogel prepared by the preparation method according to claim 8 or 9 in preparing a drug for treating arteriovenous fistula outflow tract stenosis and / or venous graft stenosis.

Citation Information

Cited By

  • Drug sustained-release preparation for inhibiting vascular intimal hyperplasia as well as preparation method and application of drug sustained-release preparation

    CN121003584A